LJPC La Jolla Pharmaceutical Company

7.38
+0.09  (+1%)
Previous Close 7.29
Open 7.34
Price To Book 6.83
Market Cap 199822142
Shares 27,076,171
Volume 566,679
Short Ratio
Av. Daily Volume 1,153,279

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2H 2019.
LJPC‑401
Hereditary Hemochromatosis
Pivotal data due mid-2020.
LJPC-401
Beta thalassemia patients suffering from iron overload
PDUFA date under priority review scheduled for February 28, 2018. Approval announced December 21, 2017.
GiaprezaTM (angiotensin II)
Increase blood pressure in adults with septic or other distributive shock

Latest News

  1. La Jolla Pharmaceutical Company Appoints Darryl Wellinghoff as Chief Commercial Officer
  2. Edited Transcript of LJPC earnings conference call or presentation 4-Mar-19 9:30pm GMT
  3. La Jolla Pharmaceutical Company to Present at the 39th Annual Cowen Healthcare Conference
  4. Does La Jolla Pharmaceutical Company’s (NASDAQ:LJPC) CEO Pay Reflect Performance?
  5. Do Options Traders Know Something About La Jolla Pharmaceutical (LJPC) Stock We Don't?
  6. The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings
  7. La Jolla Pharmaceutical Co (LJPC) Q4 2018 Earnings Conference Call Transcript
  8. La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2018 and Highlights Recent Corporate Progress and Key Objectives
  9. La Jolla Pharmaceutical Company to Release Fourth Quarter and Full Year 2018 Financial Results on March 4, 2019
  10. La Jolla Pharmaceutical Company Announces Data Presentations at the Society of Critical Care Medicine’s 48th Critical Care Congress
  11. Analysis: Positioning to Benefit within ArcBest, International Game Technology, eHealth, Syros Pharmaceuticals, La Jolla Pharmaceutical, and Virtus Investment Partners — Research Highlights Growth, Revenue, and Consolidated Results
  12. Large Biotech Stock Holder Slashes Stake, but Insiders Are Buying
  13. Biotech Companies to Watch
  14. HC Wainwright Slashes La Jolla Pharma Price Target, Estimates On Below-Expectation Guidance
  15. Here's Why La Jolla Pharmaceutical Tumbled Today
  16. La Jolla Stock Plummets 44% After Disappointing Drug Sales Projections
  17. La Jolla Pharmaceutical's stock plummets to pace Nasdaq losers after downbeat drug guidance
  18. La Jolla Pharmaceutical Company Highlights Recent Corporate Progress and Key Objectives
  19. La Jolla Pharmaceutical Company to Present at the 37th Annual J.P. Morgan Healthcare Conference
  20. Hedge Funds Are Crazy About La Jolla Pharmaceutical Company (LJPC)